ACE2 News and Research

RSS

New research proposes innovative antibody-based treatment to prevent SARS-CoV-2 viral entry

A brief report by researchers at the University of Virginia, USA, proposes using an antibody-based treatment with a plug-and-play strategy to inhibit the ability of SARS-CoV-2 to invade human cells.

17 Mar 2021

Researchers develop innovative profiling methods for SARS-CoV-2 infection

A team of researchers from various institutions in the USA used RNA-sequencing data and other methods to profile unique genes and other characteristics associated with SARS-CoV-2 in New York City (NYC).

17 Mar 2021

Novel protein construct prevents lethal COVID-19 in mice

Researchers in the United States have developed a novel protein that prevented lethal disease among mice infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 Mar 2021

SARS-CoV-2 in wastewater may pose risks to marine mammals

Endangered marine mammals — seals, dolphins, whales, and otters — are almost as vulnerable as humans in becoming infected from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Researchers from the Dalhousie University in Canada published a study in Science of The Total Environment that found human wastewater as a potential mode of coronavirus transmission to animals.

16 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Using pseudoviruses with single amino acid substitutions, researchers found that mutations in SARS-CoV-2 reduce monoclonal antibody neutralization differently. However, convalescent sera samples did not lose neutralization potency many and were also effective against the B.1.1.7 (UK-derived) strain.

16 Mar 2021

White-tailed deer susceptible to SARS-CoV-2, finds study

White-tailed deer have been observed to be susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They can also transmit the virus both through direct and indirect contact to one another, researchers find. The research paper is available to be read online in the Journal of Virology.

15 Mar 2021

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

Neutralizing nanobodies effective against SARS-CoV-2 variants

Nanobodies have different mechanisms to neutralize viruses, and some target epitopes not accessible to monoclonal antibodies, making them an alternative for developing therapies for COVID-19.

15 Mar 2021

Soluble ACE2 level correlates with COVID-19 outcomes

Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.

14 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

11 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study

Researchers found about 10% of blood monocytes in coronavirus disease 2019 (COVID-19) patients are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These monocytes then die, leading to the release of cytokines – a feature associated with severe and critical COVID-19.

11 Mar 2021

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.

11 Mar 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

10 Mar 2021